Add to ORKGRandomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI
Introduction:We sought to determine the efficacy of using both irinotecan- and etoposide-containing ...
Introduction: In a literature meta-analysis, we showed survival benefits for regimens including cisp...
Background: Paclitaxel administered in combination with a topoisomerase-II inhibitor (such as etopos...
Purpose: The combination of irinotecan and cisplatin (IP) has shown at least comparable efficacy to ...
Background: The combination of etoposide plus cisplatin (EP) is considered to be standard therapy fo...
Purpose This randomized phase III study was designed to compare the efficacy and safety of irinoteca...
IntroductionTo determine whether irinotecan maintenance therapy in extensive disease-small cell lung...
textabstractAs a dose-response relationship has been suggested for cisplatin, it appeared attractive...
INTRODUCTION: We sought to determine the efficacy of using both irinotecan-and etoposide-containing ...
Background: Etoposide is a highly schedule-dependent drug. We investigated combination chemotherapy ...
The article discusses the use of irinotecan, cisplatin, and etoposide for the treatment of limited-s...
Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in pati...
PURPOSE: Irinotecan plus cisplatin has been previously documented to be effective in the treatment o...
Purpose: We performed a prospective randomized clinical trial to determine whether higher doses of e...
BackgroundEtoposide-platinum doublet therapy has been the American standard first-line management fo...
Introduction:We sought to determine the efficacy of using both irinotecan- and etoposide-containing ...
Introduction: In a literature meta-analysis, we showed survival benefits for regimens including cisp...
Background: Paclitaxel administered in combination with a topoisomerase-II inhibitor (such as etopos...
Purpose: The combination of irinotecan and cisplatin (IP) has shown at least comparable efficacy to ...
Background: The combination of etoposide plus cisplatin (EP) is considered to be standard therapy fo...
Purpose This randomized phase III study was designed to compare the efficacy and safety of irinoteca...
IntroductionTo determine whether irinotecan maintenance therapy in extensive disease-small cell lung...
textabstractAs a dose-response relationship has been suggested for cisplatin, it appeared attractive...
INTRODUCTION: We sought to determine the efficacy of using both irinotecan-and etoposide-containing ...
Background: Etoposide is a highly schedule-dependent drug. We investigated combination chemotherapy ...
The article discusses the use of irinotecan, cisplatin, and etoposide for the treatment of limited-s...
Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in pati...
PURPOSE: Irinotecan plus cisplatin has been previously documented to be effective in the treatment o...
Purpose: We performed a prospective randomized clinical trial to determine whether higher doses of e...
BackgroundEtoposide-platinum doublet therapy has been the American standard first-line management fo...
Introduction:We sought to determine the efficacy of using both irinotecan- and etoposide-containing ...
Introduction: In a literature meta-analysis, we showed survival benefits for regimens including cisp...
Background: Paclitaxel administered in combination with a topoisomerase-II inhibitor (such as etopos...